SrasV1, PascalFrancis, Corpus, bibRecord, 000684

New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus

Identifieur interne : 000684 ( PascalFrancis/Corpus ); précédent : 000683; suivant : 000685

New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus

Auteurs : John S. Oxford ; Shobana Balasingam ; Charlotte Chan ; Andrew Catchpole ; Robert Lambkin

Source :

Antiviral chemistry & chemotherapy [ 0956-3202 ] ; 2005.

RBID : Pascal:05-0232555

Descripteurs français

Pascal (Inist)
- Antiviral, Médicament, Vaccin, Prévention, Immunoprophylaxie, Santé publique, Virus syndrome respiratoire aigu sévère, Relation structure activité, Syndrome respiratoire aigu sévère, Article synthèse.

English descriptors

KwdEn :
- Antiviral, Drug, Immunoprophylaxis, Prevention, Public health, Review, Severe acute respiratory syndrome, Severe acute respiratory syndrome virus, Structure activity relation, Vaccine.

Abstract

Severe acute respiratory syndrome (SARS) is caused by one of two recently discovered coronaviruses. The virus is emergent from South East (SE) Asian mammals: either the civet cat, a related species or a rat species. The virus has a long incubation period and low reproduction number (R₀ value) and hence the first outbreak in 2004 was controlled by hygiene and quarantine. However, the healthcare system was compromised and the economic cost was extremely high. Fortunately, the virus is easily cultivated in Vero E6 cells and therefore the search for new antivirals and vaccines was initiated within weeks of the discovery of the virus using classic techniques of cell culture and electron microscopy. Molecular diagnostics facilitated rapid and accurate diagnosis, a key factor in containing the outbreak. The broad-spectrum molecule ribavirin was used in SE Asia in infected patients alongside corticosteroids. In retrospect, many patients survived due to careful nursing. The only currently accepted intervention is interferon. Coronavirus replicon systems should facilitate rapid screening of new inhibitors and the complex mechanism of viral replication will ensure that drugs are developed against at least five molecular targets, in particular the viral protease.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0956-3202`
A03		`1`		`@0 Antivir. chem. chemother.`
A05				`@2 16`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus`
A11	`01`	`1`		`@1 OXFORD (John S.)`
A11	`02`	`1`		`@1 BALASINGAM (Shobana)`
A11	`03`	`1`		`@1 CHAN (Charlotte)`
A11	`04`	`1`		`@1 CATCHPOLE (Andrew)`
A11	`05`	`1`		`@1 LAMBKIN (Robert)`
A14	`01`			`@1 Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry @2 London @3 GBR @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut.`
A20				`@1 13-21`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 22101 @5 354000121167610020`
A44				`@0 0000 @1 © 2005 INIST-CNRS. All rights reserved.`
A45				`@0 2 p.1/4`
A47	`01`	`1`		`@0 05-0232555`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Antiviral chemistry & chemotherapy`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Severe acute respiratory syndrome (SARS) is caused by one of two recently discovered coronaviruses. The virus is emergent from South East (SE) Asian mammals: either the civet cat, a related species or a rat species. The virus has a long incubation period and low reproduction number (R₀ value) and hence the first outbreak in 2004 was controlled by hygiene and quarantine. However, the healthcare system was compromised and the economic cost was extremely high. Fortunately, the virus is easily cultivated in Vero E6 cells and therefore the search for new antivirals and vaccines was initiated within weeks of the discovery of the virus using classic techniques of cell culture and electron microscopy. Molecular diagnostics facilitated rapid and accurate diagnosis, a key factor in containing the outbreak. The broad-spectrum molecule ribavirin was used in SE Asia in infected patients alongside corticosteroids. In retrospect, many patients survived due to careful nursing. The only currently accepted intervention is interferon. Coronavirus replicon systems should facilitate rapid screening of new inhibitors and the complex mechanism of viral replication will ensure that drugs are developed against at least five molecular targets, in particular the viral protease.
C02	`01`	`X`		`@0 002B02S05`
C03	`01`	`X`	`FRE`	`@0 Antiviral @5 11`
C03	`01`	`X`	`ENG`	`@0 Antiviral @5 11`
C03	`01`	`X`	`SPA`	`@0 Antiviral @5 11`
C03	`02`	`X`	`FRE`	`@0 Médicament @5 12`
C03	`02`	`X`	`ENG`	`@0 Drug @5 12`
C03	`02`	`X`	`SPA`	`@0 Medicamento @5 12`
C03	`03`	`X`	`FRE`	`@0 Vaccin @5 14`
C03	`03`	`X`	`ENG`	`@0 Vaccine @5 14`
C03	`03`	`X`	`SPA`	`@0 Vacuna @5 14`
C03	`04`	`X`	`FRE`	`@0 Prévention @5 15`
C03	`04`	`X`	`ENG`	`@0 Prevention @5 15`
C03	`04`	`X`	`SPA`	`@0 Prevención @5 15`
C03	`05`	`X`	`FRE`	`@0 Immunoprophylaxie @5 16`
C03	`05`	`X`	`ENG`	`@0 Immunoprophylaxis @5 16`
C03	`05`	`X`	`SPA`	`@0 Inmunoprofilaxia @5 16`
C03	`06`	`X`	`FRE`	`@0 Santé publique @5 17`
C03	`06`	`X`	`ENG`	`@0 Public health @5 17`
C03	`06`	`X`	`SPA`	`@0 Salud pública @5 17`
C03	`07`	`X`	`FRE`	`@0 Virus syndrome respiratoire aigu sévère @2 NW @5 18`
C03	`07`	`X`	`ENG`	`@0 Severe acute respiratory syndrome virus @2 NW @5 18`
C03	`07`	`X`	`SPA`	`@0 Severe acute respiratory syndrome virus @2 NW @5 18`
C03	`08`	`X`	`FRE`	`@0 Relation structure activité @5 19`
C03	`08`	`X`	`ENG`	`@0 Structure activity relation @5 19`
C03	`08`	`X`	`SPA`	`@0 Relación estructura actividad @5 19`
C03	`09`	`X`	`FRE`	`@0 Syndrome respiratoire aigu sévère @2 NM @5 20`
C03	`09`	`X`	`ENG`	`@0 Severe acute respiratory syndrome @2 NM @5 20`
C03	`09`	`X`	`SPA`	`@0 Síndrome respiratorio agudo severo @2 NM @5 20`
C03	`10`	`X`	`FRE`	`@0 Article synthèse @5 22`
C03	`10`	`X`	`ENG`	`@0 Review @5 22`
C03	`10`	`X`	`SPA`	`@0 Artículo síntesis @5 22`
C07	`01`	`X`	`FRE`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`ENG`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`SPA`	`@0 Coronavirus @2 NW`
C07	`02`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`04`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`04`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`05`	`X`	`FRE`	`@0 Virose`
C07	`05`	`X`	`ENG`	`@0 Viral disease`
C07	`05`	`X`	`SPA`	`@0 Virosis`
C07	`06`	`X`	`FRE`	`@0 Infection`
C07	`06`	`X`	`ENG`	`@0 Infection`
C07	`06`	`X`	`SPA`	`@0 Infección`
C07	`07`	`X`	`FRE`	`@0 Appareil respiratoire pathologie @5 61`
C07	`07`	`X`	`ENG`	`@0 Respiratory disease @5 61`
C07	`07`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 61`
C07	`08`	`X`	`FRE`	`@0 Poumon pathologie @5 62`
C07	`08`	`X`	`ENG`	`@0 Lung disease @5 62`
C07	`08`	`X`	`SPA`	`@0 Pulmón patología @5 62`
N21				`@1 157`

Format Inist (serveur)

NO :	PASCAL 05-0232555 INIST
ET :	New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus
AU :	OXFORD (John S.); BALASINGAM (Shobana); CHAN (Charlotte); CATCHPOLE (Andrew); LAMBKIN (Robert)
AF :	Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry/London/Royaume-Uni (1 aut., 2 aut., 3 aut., 4 aut., 5 aut.)
DT :	Publication en série; Niveau analytique
SO :	Antiviral chemistry & chemotherapy; ISSN 0956-3202; Royaume-Uni; Da. 2005; Vol. 16; No. 1; Pp. 13-21; Bibl. 2 p.1/4
LA :	Anglais
EA :	Severe acute respiratory syndrome (SARS) is caused by one of two recently discovered coronaviruses. The virus is emergent from South East (SE) Asian mammals: either the civet cat, a related species or a rat species. The virus has a long incubation period and low reproduction number (R₀ value) and hence the first outbreak in 2004 was controlled by hygiene and quarantine. However, the healthcare system was compromised and the economic cost was extremely high. Fortunately, the virus is easily cultivated in Vero E6 cells and therefore the search for new antivirals and vaccines was initiated within weeks of the discovery of the virus using classic techniques of cell culture and electron microscopy. Molecular diagnostics facilitated rapid and accurate diagnosis, a key factor in containing the outbreak. The broad-spectrum molecule ribavirin was used in SE Asia in infected patients alongside corticosteroids. In retrospect, many patients survived due to careful nursing. The only currently accepted intervention is interferon. Coronavirus replicon systems should facilitate rapid screening of new inhibitors and the complex mechanism of viral replication will ensure that drugs are developed against at least five molecular targets, in particular the viral protease.
CC :	002B02S05
FD :	Antiviral; Médicament; Vaccin; Prévention; Immunoprophylaxie; Santé publique; Virus syndrome respiratoire aigu sévère; Relation structure activité; Syndrome respiratoire aigu sévère; Article synthèse
FG :	Coronavirus; Coronaviridae; Nidovirales; Virus; Virose; Infection; Appareil respiratoire pathologie; Poumon pathologie
ED :	Antiviral; Drug; Vaccine; Prevention; Immunoprophylaxis; Public health; Severe acute respiratory syndrome virus; Structure activity relation; Severe acute respiratory syndrome; Review
EG :	Coronavirus; Coronaviridae; Nidovirales; Virus; Viral disease; Infection; Respiratory disease; Lung disease
SD :	Antiviral; Medicamento; Vacuna; Prevención; Inmunoprofilaxia; Salud pública; Severe acute respiratory syndrome virus; Relación estructura actividad; Síndrome respiratorio agudo severo; Artículo síntesis
LO :	INIST-22101.354000121167610020
ID :	05-0232555

Links to Exploration step

Pascal:05-0232555

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus</title>
<author><name sortKey="Oxford, John S" sort="Oxford, John S" uniqKey="Oxford J" first="John S." last="Oxford">John S. Oxford</name>
<affiliation><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Balasingam, Shobana" sort="Balasingam, Shobana" uniqKey="Balasingam S" first="Shobana" last="Balasingam">Shobana Balasingam</name>
<affiliation><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chan, Charlotte" sort="Chan, Charlotte" uniqKey="Chan C" first="Charlotte" last="Chan">Charlotte Chan</name>
<affiliation><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Catchpole, Andrew" sort="Catchpole, Andrew" uniqKey="Catchpole A" first="Andrew" last="Catchpole">Andrew Catchpole</name>
<affiliation><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lambkin, Robert" sort="Lambkin, Robert" uniqKey="Lambkin R" first="Robert" last="Lambkin">Robert Lambkin</name>
<affiliation><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0232555</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0232555 INIST</idno>
<idno type="RBID">Pascal:05-0232555</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000684</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus</title>
<author><name sortKey="Oxford, John S" sort="Oxford, John S" uniqKey="Oxford J" first="John S." last="Oxford">John S. Oxford</name>
<affiliation><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Balasingam, Shobana" sort="Balasingam, Shobana" uniqKey="Balasingam S" first="Shobana" last="Balasingam">Shobana Balasingam</name>
<affiliation><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chan, Charlotte" sort="Chan, Charlotte" uniqKey="Chan C" first="Charlotte" last="Chan">Charlotte Chan</name>
<affiliation><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Catchpole, Andrew" sort="Catchpole, Andrew" uniqKey="Catchpole A" first="Andrew" last="Catchpole">Andrew Catchpole</name>
<affiliation><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lambkin, Robert" sort="Lambkin, Robert" uniqKey="Lambkin R" first="Robert" last="Lambkin">Robert Lambkin</name>
<affiliation><inist:fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Antiviral chemistry & chemotherapy</title>
<title level="j" type="abbreviated">Antivir. chem. chemother.</title>
<idno type="ISSN">0956-3202</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Antiviral chemistry & chemotherapy</title>
<title level="j" type="abbreviated">Antivir. chem. chemother.</title>
<idno type="ISSN">0956-3202</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term>
<term>Drug</term>
<term>Immunoprophylaxis</term>
<term>Prevention</term>
<term>Public health</term>
<term>Review</term>
<term>Severe acute respiratory syndrome</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Structure activity relation</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antiviral</term>
<term>Médicament</term>
<term>Vaccin</term>
<term>Prévention</term>
<term>Immunoprophylaxie</term>
<term>Santé publique</term>
<term>Virus syndrome respiratoire aigu sévère</term>
<term>Relation structure activité</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Article synthèse</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is caused by one of two recently discovered coronaviruses. The virus is emergent from South East (SE) Asian mammals: either the civet cat, a related species or a rat species. The virus has a long incubation period and low reproduction number (R<sub>0</sub>
 value) and hence the first outbreak in 2004 was controlled by hygiene and quarantine. However, the healthcare system was compromised and the economic cost was extremely high. Fortunately, the virus is easily cultivated in Vero E6 cells and therefore the search for new antivirals and vaccines was initiated within weeks of the discovery of the virus using classic techniques of cell culture and electron microscopy. Molecular diagnostics facilitated rapid and accurate diagnosis, a key factor in containing the outbreak. The broad-spectrum molecule ribavirin was used in SE Asia in infected patients alongside corticosteroids. In retrospect, many patients survived due to careful nursing. The only currently accepted intervention is interferon. Coronavirus replicon systems should facilitate rapid screening of new inhibitors and the complex mechanism of viral replication will ensure that drugs are developed against at least five molecular targets, in particular the viral protease.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0956-3202</s0>
</fA01>
<fA03 i2="1"><s0>Antivir. chem. chemother.</s0>
</fA03>
<fA05><s2>16</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>OXFORD (John S.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BALASINGAM (Shobana)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>CHAN (Charlotte)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>CATCHPOLE (Andrew)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>LAMBKIN (Robert)</s1>
</fA11>
<fA14 i1="01"><s1>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>13-21</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>22101</s2>
<s5>354000121167610020</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>2 p.1/4</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0232555</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Antiviral chemistry & chemotherapy</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Severe acute respiratory syndrome (SARS) is caused by one of two recently discovered coronaviruses. The virus is emergent from South East (SE) Asian mammals: either the civet cat, a related species or a rat species. The virus has a long incubation period and low reproduction number (R<sub>0</sub>
 value) and hence the first outbreak in 2004 was controlled by hygiene and quarantine. However, the healthcare system was compromised and the economic cost was extremely high. Fortunately, the virus is easily cultivated in Vero E6 cells and therefore the search for new antivirals and vaccines was initiated within weeks of the discovery of the virus using classic techniques of cell culture and electron microscopy. Molecular diagnostics facilitated rapid and accurate diagnosis, a key factor in containing the outbreak. The broad-spectrum molecule ribavirin was used in SE Asia in infected patients alongside corticosteroids. In retrospect, many patients survived due to careful nursing. The only currently accepted intervention is interferon. Coronavirus replicon systems should facilitate rapid screening of new inhibitors and the complex mechanism of viral replication will ensure that drugs are developed against at least five molecular targets, in particular the viral protease.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S05</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>11</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>11</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>11</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Médicament</s0>
<s5>12</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Drug</s0>
<s5>12</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Medicamento</s0>
<s5>12</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Vaccin</s0>
<s5>14</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Vaccine</s0>
<s5>14</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Vacuna</s0>
<s5>14</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Prévention</s0>
<s5>15</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Prevention</s0>
<s5>15</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Prevención</s0>
<s5>15</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Immunoprophylaxie</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Immunoprophylaxis</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Inmunoprofilaxia</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Santé publique</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Public health</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Salud pública</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0>
<s2>NW</s2>
<s5>18</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>18</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>18</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Relation structure activité</s0>
<s5>19</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Structure activity relation</s0>
<s5>19</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Relación estructura actividad</s0>
<s5>19</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>22</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Review</s0>
<s5>22</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>22</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>61</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>61</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>61</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Poumon pathologie</s0>
<s5>62</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>62</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>62</s5>
</fC07>
<fN21><s1>157</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 05-0232555 INIST</NO>
<ET>New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus</ET>
<AU>OXFORD (John S.); BALASINGAM (Shobana); CHAN (Charlotte); CATCHPOLE (Andrew); LAMBKIN (Robert)</AU>
<AF>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts and the London Queen Mary's School of Medicine and Dentistry/London/Royaume-Uni (1 aut., 2 aut., 3 aut., 4 aut., 5 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Antiviral chemistry & chemotherapy; ISSN 0956-3202; Royaume-Uni; Da. 2005; Vol. 16; No. 1; Pp. 13-21; Bibl. 2 p.1/4</SO>
<LA>Anglais</LA>
<EA>Severe acute respiratory syndrome (SARS) is caused by one of two recently discovered coronaviruses. The virus is emergent from South East (SE) Asian mammals: either the civet cat, a related species or a rat species. The virus has a long incubation period and low reproduction number (R<sub>0</sub>
 value) and hence the first outbreak in 2004 was controlled by hygiene and quarantine. However, the healthcare system was compromised and the economic cost was extremely high. Fortunately, the virus is easily cultivated in Vero E6 cells and therefore the search for new antivirals and vaccines was initiated within weeks of the discovery of the virus using classic techniques of cell culture and electron microscopy. Molecular diagnostics facilitated rapid and accurate diagnosis, a key factor in containing the outbreak. The broad-spectrum molecule ribavirin was used in SE Asia in infected patients alongside corticosteroids. In retrospect, many patients survived due to careful nursing. The only currently accepted intervention is interferon. Coronavirus replicon systems should facilitate rapid screening of new inhibitors and the complex mechanism of viral replication will ensure that drugs are developed against at least five molecular targets, in particular the viral protease.</EA>
<CC>002B02S05</CC>
<FD>Antiviral; Médicament; Vaccin; Prévention; Immunoprophylaxie; Santé publique; Virus syndrome respiratoire aigu sévère; Relation structure activité; Syndrome respiratoire aigu sévère; Article synthèse</FD>
<FG>Coronavirus; Coronaviridae; Nidovirales; Virus; Virose; Infection; Appareil respiratoire pathologie; Poumon pathologie</FG>
<ED>Antiviral; Drug; Vaccine; Prevention; Immunoprophylaxis; Public health; Severe acute respiratory syndrome virus; Structure activity relation; Severe acute respiratory syndrome; Review</ED>
<EG>Coronavirus; Coronaviridae; Nidovirales; Virus; Viral disease; Infection; Respiratory disease; Lung disease</EG>
<SD>Antiviral; Medicamento; Vacuna; Prevención; Inmunoprofilaxia; Salud pública; Severe acute respiratory syndrome virus; Relación estructura actividad; Síndrome respiratorio agudo severo; Artículo síntesis</SD>
<LO>INIST-22101.354000121167610020</LO>
<ID>05-0232555</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000684 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000684 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:05-0232555
   |texte=   New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus

New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri